Cna Financial Corp Zentalis Pharmaceuticals, Inc. Transaction History

Cna Financial Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$20.23 - $31.73 $23,669 - $37,124	-1,170 Reduced 10.01%	10,516 $228,000
Q2 2022 Aug 09, 2022	BUY	$17.91 - $52.25 $62,864 - $183,397	3,510 Added 42.93%	11,686 $328,000
Q1 2022 May 10, 2022	BUY	$41.58 - $80.89 $9,147 - $17,795	220 Added 2.77%	8,176 $377,000
Q4 2021 Feb 11, 2022	SELL	$66.92 - $84.79 $94,357 - $119,553	-1,410 Reduced 15.05%	7,956 $669,000
Q3 2021 Nov 12, 2021	BUY	$46.83 - $73.5 $14,049 - $22,050	300 Added 3.31%	9,366 $624,000
Q2 2021 Aug 12, 2021	SELL	$37.41 - $62.25 $89,035 - $148,155	-2,380 Reduced 20.79%	9,066 $482,000
Q1 2021 May 14, 2021	BUY	$35.69 - $52.72 $95,649 - $141,289	2,680 Added 30.57%	11,446 $497,000
Q4 2020 Feb 12, 2021	BUY	$31.71 - $57.97 $12,049 - $22,028	380 Added 4.53%	8,766 $455,000
Q3 2020 Nov 12, 2020	BUY	$27.03 - $47.97 $80,008 - $141,991	2,960 Added 54.55%	8,386 $274,000
Q2 2020 Aug 13, 2020	BUY	$23.2 - $54.8 $125,883 - $297,344	5,426 New	5,426 $261,000

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Cna Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Cna Financial Corp with notifications on news.